MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Boston Scientific Corp.

Closed

SectorHealthcare

98.71 -1.35

Overview

Share price change

24h

Current

Min

97.25

Max

100

Key metrics

By Trading Economics

Income

-138M

562M

Sales

352M

4.6B

P/E

Sector Avg

80.704

63.778

EPS

0.7

Profit margin

12.322

Employees

53,000

EBITDA

-41M

1B

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+20.26% upside

Dividends

By Dow Jones

Next Earnings

23 kwi 2025

Market Stats

By TradingEconomics

Market Cap

-2.9B

149B

Previous open

100.06

Previous close

98.71

News Sentiment

By Acuity

29%

71%

87 / 386 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

Boston Scientific Corp. Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

3 mar 2025, 12:35 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific to Buy Rest of SoniVie for Initial $360 Million

5 lut 2025, 12:23 UTC

Earnings

Boston Scientific 4Q Profit Up on Strong Cardio Device Sales

8 sty 2025, 12:33 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific to Buy Rest of Bolt Medical for $443 Million

4 lis 2024, 13:01 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific to Buy Medical-Technology Company Cortex

3 mar 2025, 11:59 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific to Pay Up to Additional $180 Million Upon Achievement of Regulatory Milestone >BSX

3 mar 2025, 11:58 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific to Buy Rest of SoniVie for Initial $360 Million >BSX

3 mar 2025, 11:58 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific Announces Agreement To Acquire SoniVie Ltd. >BSX

5 lut 2025, 21:33 UTC

Earnings

How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat -- IBD

5 lut 2025, 15:20 UTC

Earnings

How Boston Sci Leaned On Its New Heart Device For A Fourth-Quarter Beat -- IBD

5 lut 2025, 11:39 UTC

Earnings

Boston Scientific Sees 1Q Organic Sales Up 14%-16% >BSX

5 lut 2025, 11:39 UTC

Earnings

Boston Scientific Sees 1Q Sales Up 17%-19% >BSX

5 lut 2025, 11:38 UTC

Earnings

Boston Scientific Sees 2025 Organic Sales Up 10%-12% >BSX

5 lut 2025, 11:38 UTC

Earnings

Boston Scientific Sees 2025 Sales Up 12.5%-14.5% >BSX

5 lut 2025, 11:37 UTC

Earnings

Boston Scientific 4Q Organic Sales Up 19.5% >BSX

5 lut 2025, 11:37 UTC

Earnings

Boston Scientific 4Q Adj EPS 70c >BSX

5 lut 2025, 11:37 UTC

Earnings

Boston Scientific Sees FY EPS $1.86-EPS $1.93 >BSX

5 lut 2025, 11:37 UTC

Earnings

Boston Scientific 4Q Sales $4.56B >BSX

5 lut 2025, 11:37 UTC

Earnings

Boston Scientific Sees FY Adj EPS $2.80-Adj EPS $2.87 >BSX

5 lut 2025, 11:37 UTC

Earnings

Boston Scientific Sees 1Q Adj EPS 66c-Adj EPS 68c >BSX

5 lut 2025, 11:37 UTC

Earnings

Boston Scientific Sees 1Q EPS 43c-EPS 45c >BSX

5 lut 2025, 11:37 UTC

Earnings

Boston Scientific 4Q EPS 38c >BSX

8 sty 2025, 12:10 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific Sees Deal More Dilutive on GAAP Basis >BSX

8 sty 2025, 12:09 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific Sees Deal Slightly Dilutive to Adj EPS in 2025 >BSX

8 sty 2025, 12:09 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific to Pay Up to Another $221M After Certain Regulatory Milestones >BSX

8 sty 2025, 12:08 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific: Deal Includes Upfront Payment of About $443M for 74% Stake Not yet Owned >BSX

8 sty 2025, 12:07 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific: Buyout to Further Co's Strategy to Address Coronary and Peripheral Disease >BSX

8 sty 2025, 12:07 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific: Buyout to Expand Cardiovascular Portfolio With Complementary, Differentiated Calcium Modification Platform >BSX

8 sty 2025, 12:00 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific Announces Agreement To Acquire Bolt Medical, Inc. >BSX

25 lis 2024, 12:00 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific Announces Agreement To Acquire Intera Oncology(R) Inc. >BSX

15 lis 2024, 13:43 UTC

Acquisitions, Mergers, Takeovers

Boston Scientific Closes Acquisition Of Axonics, Inc. >BSX AXNX

Peer Comparison

Price change

Boston Scientific Corp. Forecast

Price Target

By TipRanks

20.26% upside

12 Months Forecast

Average 120.32 USD  20.26%

High 135 USD

Low 108 USD

Based on 23 Wall Street analysts offering 12 month price targets forBoston Scientific Corp. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

23 ratings

22

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

99.3 / 101.49Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

No Evidence

Sentiment

By Acuity

87 / 386 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.